Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 136

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 136
---
ABILITIES AND STOCKHOLDERS’ EQUITY                                                                                                                                                    |     |   |      |     |        5,630 |   |     |     |          460 |   |

<div align='center'>The accompanying notes are an integral part of these financial statements.

F-30</div>

REVIUM RX.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

U.S. dollars in thousands (except share and per share data)

|                                                                |     |      |     | For the year ended |            |     |      |            |
|:---------------------------------------------------------------|:----|:-----|:----|-------------------:|-----------:|:----|-----:|-----------:|
|                                                                |     | Note |     |       December 31, |            |     |      |            |
|                                                                |     |      |     |               2023 |            |     | 2022 |            |
| Operating expenses                                             |     |      |     |                    |            |     |      |            |
| Research and development expenses                              |     | 7a   |     |                    |          7 |     |      |         67 |
| General and administrative expenses                            |     | 7b   |     |                    |        673 |     |      |      1,124 |
| Operating loss                                                 |     |      |     |                    |        680 |     |      |      1,191 |
| Financial expenses, net                                        |     |      |     |                    |          3 |     |      |         22 |
| Net loss                                                       |     |      |     |                    |        683 |     |      |      1,213 |
| Net loss per common share – basic and diluted                  |     |      |     |                    |       0.02 |     |      |       0.04 |
| Weighted average common shares outstanding – basic and diluted |     |      |     |                    | 29,358,453 |     |      | 28,110,869 |

<div align='center'>The accompanying notes are an integral part of these financial statements.

F-31</div>

REVIUM RX.

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

U.S. dollars in thousands (except share data)

|                                          |     | Common Stock: 
 Shares (*)    |            |     | Common Stock: 
 Amount        |    |   |